BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...
Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a ...